Protein C News and Research

RSS

Isogenica, Phylogica partner in Phylomer peptide development

Isogenica Ltd today announced that it has entered into an agreement with Australian based biopharmaceutical company Phylogica to use Isogenica’s CIS display technology to optimize the performance of three of Phylogica’s lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases, such as Rheumatoid Arthritis and Inflammatory Bowel Disease.

2 Feb 2010

Researchers identify a key piece in the ageing process

Understanding how aged and damaged mother cells manage to form new and undamaged daughter cells is one of the toughest riddles of ageing, but scientists now know how yeast cells do it. In a groundbreaking study researchers from the University of Gothenburg, Sweden, show how the daughter cell uses a mechanical "conveyor belt" to dump damaged proteins in the mother cell.

2 Feb 2010

Argonaute binds to microRNA and shuts down protein production

Johns Hopkins scientists believe they may have figured out how genetic snippets called microRNAs are able to shut down the production of some proteins.

2 Feb 2010

Gene mutation can trigger preterm births, says study

Mutation of a gene that helps protect the body from genetic instability leads to cellular and molecular changes in the pregnant uterus that trigger premature birth, according to a study appearing online Feb. 1 in the Journal of Clinical Investigation.

2 Feb 2010

New therapeutic made from tobacco plants shown to arrest West Nile virus infection

A new therapeutic made from tobacco plants has been shown to arrest West Nile virus infection, according to a new study by Arizona State University scientist Qiang Chen and his colleagues.

2 Feb 2010

EPO to grant patent notice to BioMimetic Therapeutics

BioMimetic Therapeutics, Inc. announced today the European Patent Office (EPO) intends to grant patent application No. 05803356 titled “Platelet-Derived Growth Factor Compositions and Methods of Use Thereof”.

2 Feb 2010

FDA and PATH collaborate to advance pneumococcal vaccine development for children

The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

2 Feb 2010

MSU scientist discovers the process that causes retinal cells to die

Scientists have long known that high blood sugar levels from diabetes damage blood vessels in the eye, but they didn't know why or how. Now a Michigan State University scientist has discovered the process that causes retinal cells to die, which could lead to new treatments that halt the damage.

2 Feb 2010

NanoInk launches configured protein array kit from its Nano BioDiscovery Division

NanoInk, Inc.®, a global leader in nanotechnology, is pleased to announce the launch of its first completely configured protein array kit from its Nano BioDiscovery™ Division. Based on the patented Dip Pen Nanolithography® (DPN®) platform, NanoInk's fluorescent assays enable nanoscale detection of clinically relevant proteins.

2 Feb 2010

Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza

Romark Laboratories announced that it has initiated enrollment of patients in a clinical trial of Alinia® (nitazoxanide) for treating acute uncomplicated influenza including illness caused by the currently circulating H1N1 strain.

1 Feb 2010

Researchers design bioactive nanomaterial that promotes cartilage growth

Northwestern University researchers are the first to design a bioactive nanomaterial that promotes the growth of new cartilage in vivo and without the use of expensive growth factors. Minimally invasive, the therapy activates the bone marrow stem cells and produces natural cartilage.

1 Feb 2010

YM BioSciences-Cytopia merger complete

YM BioSciences Inc., announced that the merger of Cytopia Limited, the Australian biopharmaceutical company, into YM under a Scheme of Arrangement, has been concluded.

1 Feb 2010

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.

1 Feb 2010

New testing method for early detection of cancer

A new testing method is being developed to detect cancer soon after the tumor has formed. It will identify characteristic substances in the blood which accompany a certain type of tumor. The first steps in the development have already been completed.

1 Feb 2010

Study shows nutritional deficiency, stunted growth and obesity are common among Cameroonian teenagers

There are major differences in how well nourished Cameroonian teenagers are. Differences between city/countryside, boys/girls, and among individuals with high and low socio-economic status are described by Léonie Nzefa Dapi in the dissertation she is defending at Umeå University in Sweden.

1 Feb 2010

Oxford Nanopore Technologies raises $28M in new funding

Oxford Nanopore Technologies Ltd., a privately held company that is developing a disruptive technology platform for the electronic, label-free analysis of single molecules, today announced that it has raised £17.4 million ($28 million) in new funding.

From Oxford Nanopore Technologies 1 Feb 2010

IpAuctions to auction Predicant Biosciences patents, certain intellectual property of Perlegen

IpAuctions, Inc. is selling the patents and patent applications developed by Predicant Biosciences, formerly called BioSpect, and certain intellectual property of Perlegen.

1 Feb 2010

Musical video to teach basics of biotechnology

The video will be made available to high school students across North Carolina to help teach them how biotechnology harnesses cellular machinery to cure diseases, detect biohazards and manufacture new materials.

30 Jan 2010

Lanzoprazole and astemizole hold promise for early detection of AD

Investigators from the International Center for Biomedicine and the University of Chile, in collaboration with the Center for Bioinformatics of the Universidad de Talca, have discovered that two drugs, the benzimidazole derivatives lanzoprazole and astemizole, may be suitable for use as PET (positron emission tomography) radiotracers and enable imaging for the early detection of Alzheimer's Disease. The study is published in the current issue of the Journal of Alzheimer's Disease.

30 Jan 2010

New biomarker may predict treatment outcomes in RA patients

Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.

30 Jan 2010